Dataset Information

A novel antimalarial agent that inhibits protein synthesis in Plasmodium falciparum

ABSTRACT: Drug resistance to nearly all antimalarials following their rollout underscores the need for novel chemotypes with novel mode of action to replenish the antimalarial drug-development pipeline. We identified a novel class of compounds in the antimalarial armory. Compound 31, characterized by a hydroxybenzamide scaffold, displays potent activity against blood-stage and late sexual stages of Plasmodium falciparum and no toxicity in human cells. Resistance selection studies with 31 identified a novel point mutation in the P. falciparum multidrug-resistance protein 1 (pfmdr1) gene, which was confirmed by CRISPR/Cas9-based gene editing as the primary mediator of resistance. Despite this, no cross-resistance towards first-line antimalarials were identified. Proteomics studies indicated that the primary mode of action of 31 is through direct binding to cytosolic ribosomal subunits, thereby inhibiting protein synthesis in the parasite. Taken together, compound 31 is a promising starting point for the development of a next-generation antimalarial.

INSTRUMENT(S):

ORGANISM(S): Plasmodium Falciparum Nf54

SUBMITTER: Lorenzo Bizzarri

LAB HEAD: Anna Hirsch

PROVIDER: PXD065399 | Pride | 2025-12-08

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	checksum.txt	Txt
	iSPP_Pf_DIA-NN_fullReport.txt	Txt
	iSPP_Pf_DIA-NN_gg_matrix.txt	Txt
	iSPP_Pf_DIA-NN_pg_matrix.txt	Txt
	iSPP_Pf_DIA-NN_unique_genes_matrix.txt	Txt

Items per page:

1 - 5 of 29

Publications

A Novel Antimalarial Agent that Inhibits Protein Synthesis in Plasmodium falciparum.

Bravo Patricia P Diamanti Eleonora E Hamed Mostafa M MM Bizzarri Lorenzo L Wiedemar Natalie N Passecker Armin A Brancucci Nicolas M B NMB Albisetti Anna A Gumpp Christin C Illarionov Boris B Fischer Markus M Witschel Matthias M Schehl Tobias T Hahne Hannes H Mäser Pascal P Rottmann Matthias M Hirsch Anna K H AKH

Angewandte Chemie (International ed. in English) 20251020 49

The emergence of drug resistance to nearly all antimalarials following their rollout underscores the need for novel chemotypes with novel modes of action to replenish the antimalarial drug-development pipeline. We identified a novel class of compounds in the antimalarial armory. Compound 31, characterized by a 2-hydroxyphenyl benzamide scaffold, displays potent activity against blood-stage and mature sexual stages of Plasmodium falciparum and no toxicity in human cells. Resistance selection stud ...[more]

PMID: 41116297

Similar Datasets

Project description:The increasing incidence of antimalarial drug resistance to the first-line artemisinins, and their combination partner drugs, underpins an urgent need for new antimalarial drugs, ideally with a novel mechanism of action. The recently developed 2-aminomethylphenol, JPC-3210, (MMV 892646) is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum, low cytotoxicity, potent in vivo efficacy against murine malaria, and favourable preclinical pharmacokinetics, including a lengthy plasma elimination half-life. This study demonstrates the application of a “multi-omics” workflow based on high resolution orbitrap mass spectrometry to investigate the impact of JPC-3210 on biochemical pathways within P. falciparum infected red blood cells. Metabolomics and peptidomics analysis revealed a perturbation in hemoglobin metabolism following JPC-3210 exposure. The metabolomics data demonstrated a depletion in short hemoglobin-derived peptides, while peptidomics analysis showed a depletion in longer hemoglobin-derived peptides. In order to further elucidate the mechanism responsible for inhibition of hemoglobin metabolism, we used in vitro β-hematin polymerisation assays and showed JPC-3210 to be an intermediate inhibitor of β-hematin polymerisation, about 10-fold less potent then the quinoline antimalarials. Furthermore, quantitative proteomics analysis showed that JPC-3210 treatment results in a distinct proteomic signature in comparison to other known antimalarials. Whilst JPC-3210 clustered closely with mefloquine in the metabolomics and proteomics analyses, a key differentiating signature for JPC-3210 was the significant enrichment of parasite proteins involved in regulation of translation. In conclusion, multi-omics studies using high resolution mass spectrometry revealed JPC-3210 to possess a unique mechanism of action involving inhibition of hemoglobin digestion, depletion of DNA replication and synthesis proteins, and elevation of regulators of protein translation. Importantly, this mechanism is distinct from currently-used antimalarials, suggesting that JPC-3210 warrants further investigation as a potentially useful new antimalarial agent.

Project description:Malaria remains a global health threat, with rising drug resistance accelerating the urgent need for new therapeutics. Target elucidation is a critical step in antimalarial drug discovery, enabling a deeper understanding of the molecular mechanisms of action of both existing and novel compounds. This study validates solvent-induced proteome profiling (SPP) as a proteomics-based approach for identifying drug-protein interactions in Plasmodium falciparum. SPP de-tects shifts in protein stability induced by ligand binding, allowing the identification of drug target/s without the need for compound modifications. Here, we successfully generated solvent denaturation curves for the P. falciparum pro-teome, and demonstrated the utility of SPP with five antimalarial compounds: pyrimethamine, atovaquone, cipar-gamin, MMV1557817 and OSM-S-106. In addition to measuring each compound’s impact across the full denatura-tion curve, investigating protein levels at individual solvent percentages preserved specific stability changes that would otherwise be masked in pooled analyses performed by integral SPP. This strategy was critical for the identifi-cation of the cipargamin target, non-SERCA-type Ca2+-transporting P-ATPase (PfATP4). Notably, we propose live-cell treatment SPP as a novel approach, demonstrating its ability to identify the validated target of pyrimethamine, bifunctional dihydrofolate reductase-thymidylate synthase (PfDHFR), with high specificity. We also introduced the novel one-pot mixed-drug SPP, which enables the evaluation of multiple drugs within a single lysate and experi-mental setup. This alternative method simplifies the experimental workflow and includes positive controls to affirm the performance of the experiment. Overall, this study demonstrates that SPP can be successfully applied in both ly-sate and live-cell treatment conditions to elucidate drug targets in P. falciparum, as well as providing additional in-formation regarding the mechanisms of drug action, offering insights for the optimisation of existing antimalarials and the development of novel therapies.